Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1993 1
1997 2
2001 1
2005 1
2006 2
2007 1
2010 5
2011 2
2014 6
2015 5
2016 4
2017 1
2018 4
2019 4
2020 3
2021 4
2022 14
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 22Diabetes, 5Bjour
Page 1
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC. Aldred J, et al. Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26. Neurol Ther. 2023. PMID: 37632656 Free PMC article.
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Parkinson's Disease Sleep Scale-2 (PDSS-2), 39-item Parkinson's …
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Mov …
Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC. Bergman M, et al. Arthritis Res Ther. 2022 Jun 24;24(1):155. doi: 10.1186/s13075-022-02813-x. Arthritis Res Ther. 2022. PMID: 35751108 Free PMC article. Clinical Trial.
PROs evaluated included Patient Global Assessment of Disease Activity (PtGA) by visual analog scale (VAS), patient's assessment of pain by VAS, Health Assessment Questionnaire Disability Index (HAQ-DI), morning stiffness duration and severity, 36-Item Short Form Health Survey (SF …
PROs evaluated included Patient Global Assessment of Disease Activity (PtGA) by visual analog scale (VAS), patient's assessment of pain by V …
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Noël W, Nurmohamed MT, Sfikakis PP, Sharaf M, Theander E, Smolen JS. Gossec L, et al. Arthritis Res Ther. 2023 Jun 23;25(1):109. doi: 10.1186/s13075-023-03058-y. Arthritis Res Ther. 2023. PMID: 37353788 Free PMC article.
METHODS: In PsABio (NCT02627768), a prospective, observational study, patients with PsA that were prescribed first- to third-line ustekinumab or a TNFi, and remained on that drug for 3 years, were analysed for change in baseline in PROs (EuroQol-5 dimensions health state VAS [EQ- …
METHODS: In PsABio (NCT02627768), a prospective, observational study, patients with PsA that were prescribed first- to third-line ustekinuma …
Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study.
Molife C, Winfree KB, Bailey H, D'yachkova Y, Forshaw C, Kim S, Taipale KL, Puri T. Molife C, et al. Adv Ther. 2023 Jul;40(7):3135-3168. doi: 10.1007/s12325-023-02530-0. Epub 2023 May 23. Adv Ther. 2023. PMID: 37221352 Free PMC article.
The most common tumor samples and methods for EGFR detection were EGFR-specific mutation detection tests (44.0%) and core needle biopsy (56.0%). Median time to next treatment was 14.0 (IQR 8.0-22.0) months and disease progression was the main physician-reported reason for …
The most common tumor samples and methods for EGFR detection were EGFR-specific mutation detection tests (44.0%) and core needle biopsy (56. …
Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer.
Criscitiello C, Spurden D, Piercy J, Rider A, Williams R, Mitra D, Wild R, Corsaro M, Kurosky SK, Law EH. Criscitiello C, et al. Clin Ther. 2021 Jul;43(7):1228-1244.e4. doi: 10.1016/j.clinthera.2021.04.020. Epub 2021 Jul 11. Clin Ther. 2021. PMID: 34256965
Of these, 1102 completed the FACT-B and 1083 completed the EQ-5D-5L questionnaires. The mean (SD) FACT-B total score was 99.0 (21.9). ...In addition, mean scores were comparable between the active adjuvant treatment and postadjuvant surveillance groups for the FACT-B total …
Of these, 1102 completed the FACT-B and 1083 completed the EQ-5D-5L questionnaires. The mean (SD) FACT-B total score was 99.0 (21.9). …
EQ-5D-3L Decrements by Diabetes Complications and Comorbidities in China.
Zhang Y, Wu J, Chen Y, Shi L. Zhang Y, et al. Diabetes Ther. 2020 Apr;11(4):939-950. doi: 10.1007/s13300-020-00788-z. Epub 2020 Mar 9. Diabetes Ther. 2020. PMID: 32152932 Free PMC article.
Patient characteristics, including demographic data, health conditions, oral treatment history, and health insurance coverage, were collected through self-reported questionnaires. Health utility was measured by the EQ-5D-3L scale in the questionnaire and a Chinese version …
Patient characteristics, including demographic data, health conditions, oral treatment history, and health insurance coverage, were collecte …
Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome.
Goodoory VC, Guthrie EA, Ng CE, Black CJ, Ford AC. Goodoory VC, et al. Aliment Pharmacol Ther. 2023 Feb;57(3):323-334. doi: 10.1111/apt.17356. Epub 2022 Dec 21. Aliment Pharmacol Ther. 2023. PMID: 36544055 Free article.
We used the irritable bowel syndrome quality of life (IBS-QOL) and the EQ-5D-5L questionnaires to examine characteristics associated with lower quality of life. RESULTS: The mean IBS-QOL among all 752 individuals with Rome IV IBS was 48.4 (SD 22.3) and the mean EQ- …
We used the irritable bowel syndrome quality of life (IBS-QOL) and the EQ-5D-5L questionnaires to examine characteristics associated …
Quality of life in patients with Fabry's disease: a cross-sectional study of 86 adults.
Andonian C, Beckmann J, Mayer O, Ewert P, Freiberger A, Huber M, Kaemmerer H, Kurschat C, Lagler F, Nagdyman N, Pieper L, Regenbogen C, Freilinger S. Andonian C, et al. Cardiovasc Diagn Ther. 2022 Aug;12(4):426-435. doi: 10.21037/cdt-22-215. Cardiovasc Diagn Ther. 2022. PMID: 36033224 Free PMC article.
QOL was assessed using the European Quality of Life 5 Dimensions 5 Levels questionnaire (EQ-5D-5L). RESULTS: Subjects affected by FD reported an overall reduced QOL (EQ-VAS: 71.820.0). ...
QOL was assessed using the European Quality of Life 5 Dimensions 5 Levels questionnaire (EQ-5D-5L). RESULTS: Subjects affected by FD …
Survey of perspectives of people with inherited retinal diseases on ocular gene therapy in Australia.
Mack HG, Britten-Jones AC, McGuinness MB, Chen FK, Grigg JR, Jamieson RV, Edwards TL, De Roach J, O'Hare F, Martin KR, Ayton LN. Mack HG, et al. Gene Ther. 2023 Apr;30(3-4):336-346. doi: 10.1038/s41434-022-00364-z. Epub 2022 Oct 2. Gene Ther. 2023. PMID: 36183012 Free PMC article.
We aimed to assess knowledge, attitudes, and perceptions of genetic therapies among potential recipients with IRD, using a novel instrument we designed (Attitudes to Gene Therapy-Eye (AGT-Eye)) and their associations with demographic data, self-reported visual status, and tools a …
We aimed to assess knowledge, attitudes, and perceptions of genetic therapies among potential recipients with IRD, using a novel instrument …
Laparoscopic partial splenectomy of benign tumors assisted by microwave ablation.
Li Q, Liu Z, Hu M, Ou M, Liu K, Lin W, Wu F, Cao M. Li Q, et al. J Cancer Res Ther. 2020 Sep;16(5):1002-1006. doi: 10.4103/jcrt.JCRT_816_19. J Cancer Res Ther. 2020. PMID: 33004740 Free article.
The operation time was 100-200 min (mean, 152.5 min) and ablation time was 16-35 min (mean, 22.8 min). The frequency of ablation was 4-7 times (mean, 5.3 times), and the intraoperative blood loss was 5-300 ml (mean, 138.8 ml). ...
The operation time was 100-200 min (mean, 152.5 min) and ablation time was 16-35 min (mean, 22.8 min). The frequency of ablation was …
62 results